Regulatory Bayer’s asundexian starts EU review for ischaemic stroke PharmaphorumThe EMA has started its review of Bayer's asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J J.CardiovascularRead full story pharminent June 10, 2026 (Last updated: June 10, 2026) Pharmaphorum The EMA has started its review of Bayer’s asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J J. Cardiovascular Read full story Post navigation Previous: AbbVie’s migraine drug cleared for migraine attacks on NHSNext: Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
